Operating Lease, Right-of-Use Asset of IVERIC bio, Inc. from 31 Dec 2018 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
IVERIC bio, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 31 Mar 2023.
  • IVERIC bio, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Mar 2023 was $755,000, a 42% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

IVERIC bio, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $755,000 -$540,000 -42% 31 Mar 2023 10-Q 10 May 2023 2023 Q1
Q4 2022 $1,182,000 -$340,000 -22% 31 Dec 2022 10-Q 10 May 2023 2023 Q1
Q3 2022 $1,604,000 -$144,000 -8.2% 30 Sep 2022 10-Q 04 Nov 2022 2022 Q3
Q2 2022 $2,020,000 +$49,000 +2.5% 30 Jun 2022 10-Q 26 Jul 2022 2022 Q2
Q1 2022 $1,295,000 +$1,188,000 +1110% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $1,522,000 +$1,402,000 +1168% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $1,748,000 +$1,614,000 +1204% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $1,971,000 +$1,827,000 +1269% 30 Jun 2021 10-Q 04 Aug 2021 2021 Q2
Q1 2021 $107,000 -$219,000 -67% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 $120,000 -$376,000 -76% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $134,000 -$611,000 -82% 30 Sep 2020 10-Q 03 Nov 2020 2020 Q3
Q2 2020 $144,000 -$845,000 -85% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $326,000 -$904,000 -73% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $496,000 +$496,000 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q3 2019 $745,000 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $989,000 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $1,230,000 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-Q 12 Nov 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.